Did an Alzheimer’s drug give Sue and Ken Bell extra time? Perhaps : Pictures

Ken and Susan Bell, September, 2024 in St. Charles, Mo.

Michael B. Thomas/NPR/@miketphotog

disguise caption

toggle caption

Michael B. Thomas/NPR/@miketphotog

In 2020, Sue Bell turned one of many first Alzheimer’s sufferers within the U.S. to obtain the drug now marketed as Leqembi.

4 years later, she and her husband, Ken, halted the remedy. Sue’s Alzheimer’s had reached the purpose the place her taking the drug now not made sense.

“I believe it helped,” says her husband, Ken Bell. “However I am unsure.”

That form of uncertainty is frequent with regards to Leqembi and Kisunla, two new Alzheimer’s medicine permitted since 2023.

Each medicine clear the mind of a substance known as beta-amyloid, which types the sticky plaques related to Alzheimer’s. Research present they’ll decelerate the underlying illness course of that in the end results in the loss of life of mind cells.

However neither drug restores reminiscence and cognition, and the profit to a given individual varies extensively.

“Some folks progress, different folks do fairly properly,” says Dr. Pleasure Snider, a professor of neurology and one among Sue’s docs at Washington College Faculty of Drugs in St. Louis.

Each medicine additionally value greater than $25,000 a 12 months, and might trigger mind swelling and bleeding.

A prognosis and a drug

Sue started having reminiscence issues round 2019, when she was working instead instructor.

“She’d come house and she or he’d say, I am having hassle spelling phrases and issues like that,” Ken advised me after I visited the couple in 2023 at their house in St. Charles, Missouri.

“I did not keep in mind all that,” Sue added. “That is a part of the issue.”

Sue noticed her major care physician, then a neurologist. She obtained cognitive exams, mind scans, and, finally, a prognosis: early stage Alzheimer’s.

In 2020, Sue volunteered for a research on the Washington College Faculty of Drugs in St. Louis. Researchers there have been conducting a part of a nationwide scientific trial of Leqembi, then identified by its generic identify, lecanemab.

The drug was the newest in a sequence of medicines designed to clear the mind of beta-amyloid, which types the sticky plaques which can be a trademark of Alzheimer’s. On the time, none of these medicine had been proven to gradual the lack of reminiscence and pondering.

So Sue and Ken knew lecanemab was unlikely to assist her.

“I am the sort of person who I want to assist anyone else, too.” Sue stated throughout my 2023 go to. “And that is what I used to be on this for.”

Ken hoped that if lecanemab labored even slightly, “sooner or later possibly they’d provide you with one thing that might both reverse the signs or remedy it even.”

Infusions and hope

Sue and Ken started making twice-monthly journeys to St. Louis, about half-hour away, the place she obtained lecanemab by intravenous infusion.

“Needles do not hassle me,” she stated, including that she did not expertise the mind swelling or bleeding that may be unwanted side effects of remedy.

At first, the drug appeared to assist. Sue was in a position to make a journey to New York.

“It was an awesome journey. We had 5 ladies,” Sue stated.

“It was actually six ladies,” Ken added softly.

“Oh I forgot that,” Sue stated. “It was very enjoyable. We simply walked far and wide.”

In 2023, the Meals and Drug Administration permitted lecanemab/Leqembi for treating folks within the earliest stage of Alzheimer’s.

By then, although, Sue knew her reminiscence was getting worse, regardless of the remedy.

“Oh, it is waning,” she stated on the time. “Some days I am higher than others.”

Even so, Ken and Sue stored driving from St. Charles to St. Louis for her lecanemab infusions.

A thanks be aware Susan Bell wrote simply earlier than dropping her potential to jot down.

Michael B. Thomas/NPR/@miketphotog

disguise caption

toggle caption

Michael B. Thomas/NPR/@miketphotog

Ending remedy

In late 2024, I obtained an replace throughout a video name with Ken — however not Sue.

“I did not assume it could assist to have her take part at the moment, truthfully,” he stated.

Assessments had proven that Sue’s reminiscence and pondering had declined to the purpose the place lecanemab was now not a very good possibility.

“We determined that we had been sort of losing our time coming down there on a regular basis,” Ken stated. “So we suspended taking the medicine.”

So have many different sufferers within the scientific trial of lecanemab, says Snider, the Washington College neurologist who oversaw Sue’s remedy.

“We now have a couple of folks left from that research who’re nonetheless on the remedy,” She says. “I’m stunned at how properly a few of them are doing.”

For all of its limitations, Snider says, Leqembi represents a significant change in Alzheimer’s remedy.

“Folks like Sue and Ken are the rationale we’ve got a brand new drug, and the rationale we may give hope to lots of people with this illness,” she says.

For Sue, although, hope is fading.

“She nonetheless is aware of me, nonetheless is aware of our children,” Ken says. However some days, he provides, she will get misplaced in her personal home.

On a kind of days, Sue started asking Ken to maneuver her to a care house. So Ken discovered one she appreciated.

“After she was there a couple of days, each time I’d come she would say take me again house, I do not wish to be right here anymore,” Ken says. “After a month, I introduced her again house.”

Sue continues to be at house, when she’s not at a daycare for folks with reminiscence issues. Two days every week, Ken will get assist from in-home care suppliers.

However sooner or later, Ken says, his spouse will most likely want extra care than he can prepare at house.